Literature DB >> 35726891

KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.

Heng Liu1, Jianhuang Lin1, Wei Zhou1, Renyta Moses2, Zhongping Dai1, Andrew V Kossenkov3, Ronny Drapkin4, Benjamin G Bitler5, Sergey Karakashev1, Rugang Zhang1.   

Abstract

The extent to which effector CD8+ T cells infiltrate into tumors is one of the major predictors of clinical outcome for patients with epithelial ovarian cancer (EOC). Immune cell infiltration into EOC is a complex process that could be affected by the epigenetic makeup of the tumor. Here, we have demonstrated that a lysine 4 histone H3 (H3K4) demethylase, (lysine-specific demethylase 5A; KDM5A) impairs EOC infiltration by immune cells and inhibits antitumor immune responses. Mechanistically, we found that KDM5A silenced genes involved in the antigen processing and presentation pathway. KDM5A inhibition restored the expression of genes involved in the antigen-presentation pathway in vitro and promoted antitumor immune responses mediated by CD8+ T cells in vivo in a syngeneic EOC mouse model. A negative correlation between expression of KDM5A and genes involved in the antigen processing and presentation pathway such as HLA-A and HLA-B was observed in the majority of cancer types. In summary, our results establish KDM5A as a regulator of CD8+ T-cell infiltration of tumors and demonstrate that KDM5A inhibition may provide a novel therapeutic strategy to boost antitumor immune responses. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35726891      PMCID: PMC9357105          DOI: 10.1158/2326-6066.CIR-22-0088

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  55 in total

Review 1.  Immune infiltration in human cancer: prognostic significance and disease control.

Authors:  Wolf H Fridman; Jérome Galon; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Sylvain Fisson; Diane Damotte; Franck Pagès; Eric Tartour; Catherine Sautès-Fridman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 2.  Pharmacological inhibition of KDM5A for cancer treatment.

Authors:  Guan-Jun Yang; Jia Wu; Liang Miao; Ming-Hui Zhu; Qian-Jin Zhou; Xin-Jiang Lu; Jian-Fei Lu; Chung-Hang Leung; Dik-Lung Ma; Jiong Chen
Journal:  Eur J Med Chem       Date:  2021-09-15       Impact factor: 6.514

Review 3.  Epigenetics and immunotherapy: The current state of play.

Authors:  Jennifer Dunn; Sudha Rao
Journal:  Mol Immunol       Date:  2017-05-14       Impact factor: 4.407

4.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Authors:  Ben Langmead; Cole Trapnell; Mihai Pop; Steven L Salzberg
Journal:  Genome Biol       Date:  2009-03-04       Impact factor: 13.583

5.  Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.

Authors:  John R Horton; Xu Liu; Molly Gale; Lizhen Wu; John R Shanks; Xing Zhang; Philip J Webber; Joshua S K Bell; Stephen C Kales; Bryan T Mott; Ganesha Rai; Daniel J Jansen; Mark J Henderson; Daniel J Urban; Matthew D Hall; Anton Simeonov; David J Maloney; Margaret A Johns; Haian Fu; Ajit Jadhav; Paula M Vertino; Qin Yan; Xiaodong Cheng
Journal:  Cell Chem Biol       Date:  2016-07-14       Impact factor: 8.116

6.  The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Authors:  Barbara Banelli; Elisa Carra; Federica Barbieri; Roberto Würth; Federica Parodi; Alessandra Pattarozzi; Roberta Carosio; Alessandra Forlani; Giorgio Allemanni; Daniela Marubbi; Tullio Florio; Antonio Daga; Massimo Romani
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT.

Authors:  Binbin Chen; Michael S Khodadoust; Chih Long Liu; Aaron M Newman; Ash A Alizadeh
Journal:  Methods Mol Biol       Date:  2018

8.  Antigen cross-presentation in young tumor-bearing hosts promotes CD8+ T cell terminal differentiation.

Authors:  Ardiana Moustaki; Jeremy Chase Crawford; Shanta Alli; Yiping Fan; Shannon Boi; Anthony E Zamora; Natalie M N McDonald; Gang Wu; Joy Nakitandwe; Scott Newman; Scott Foy; Antonina Silkov; Paul G Thomas; Alberto Pappo; Michael A Dyer; Elizabeth Stewart; Sara Federico; Ben Youngblood
Journal:  Sci Immunol       Date:  2022-02-04

Review 9.  Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.

Authors:  Marek Wieczorek; Esam T Abualrous; Jana Sticht; Miguel Álvaro-Benito; Sebastian Stolzenberg; Frank Noé; Christian Freund
Journal:  Front Immunol       Date:  2017-03-17       Impact factor: 7.561

Review 10.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.

Authors:  Flávia Castro; Ana Patrícia Cardoso; Raquel Madeira Gonçalves; Karine Serre; Maria José Oliveira
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.